FBRX - NASDAQ

Forte Biosciences, Inc.

Forte Biosciences, Inc.

FBRX·NASDAQ

$16.74

-7.9%
HealthcareBiotechnology

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$232.47M
EPS-4.7100
P/E Ratio-3.55
Earnings Date08/13/2026
-113.91%
Return on Invested Capital
63%
3Y+218.0%
5Y+372.0%
10Y+1.0%
-113.75%
Return on Equity
68%
3Y+219.0%
5Y+44.0%
10Y-76.0%
-83.81%
Return on Assets
45%
3Y+154.0%
5Y+10.0%
10Y-12.0%
Forte Biosciences, Inc.

Forte Biosciences, Inc. Management Team

FBRX · NASDAQ
DP

Dr. Paul A. Wagner Ph.D.

Chief Executive Officer, President & Chairman

Compensation

$1,030,848

Born 1970(Age 56)
MA

Mr. Antony A. Riley CPA

Chief Financial Officer

Compensation

$652,090

Born 1967(Age 59)
male
DB

Dr. Barbara K. Finck M.D.

Chief Medical Clinician & Director

Compensation

$488,057

Born 1947(Age 79)
MC

Mr. Christopher Roenfeldt

Chief Operating Officer

male
fbrx

Forte Biosciences, Inc. Insider Positioning

FBRX · NASDAQ

During the last 12 months, insiders have purchased $255K worth of FBRX shares, with no selling activity reported.

3 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

3-6 Months

Bought

9.7K

254.83K

Sold

0

0.00

Net Activity

+255K

+$255K

6-9 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

9-12 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

Top Buyers

1
RAA

Riley Antony A

Officer: Chief Financial Officer

9.7K shares•1 transactions

$255K

Top Sellers

No selling activity

Insider Activity Analysis

Net Insider Sentiment

Bullish

Strong bullish signal with $255K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.

Buy/Sell Ratio

∞:1

Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.

Insider Participation

High Buying

1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.

Insider Activity Insight

Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.

SEC Filings

FBRX - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
DEF 14A

DEF 14A 2026

N/A

April 29, 2026
May 29, 2026
2026
View Filing
DEF 14A

DEF 14A 2025

N/A

April 30, 2025
May 29, 2025
2025
View Filing
DEF 14A

DEF 14A 2025

N/A

December 31, 2024
January 24, 2025
2025
View Filing
DEF 14A

DEF 14A 2024

N/A

July 30, 2024
August 20, 2024
2024
View Filing
DEF 14A

DEF 14A 2022

N/A

April 29, 2022
June 01, 2022
2022
View Filing
DEF 14A

DEF 14A 2021

N/A

April 30, 2021
May 28, 2021
2021
View Filing
DEF 14A

DEF 14A 2019

N/A

April 19, 2019
May 29, 2019
2019
View Filing
DEF 14A

DEF 14A 2018

N/A

April 30, 2018
June 21, 2018
2018
View Filing
Showing 1 to 8 of 8 filings

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.